Möchten Sie immer auf dem neuesten Stand bleiben?

Proposed trial to compare two oral single agents Agreement secured on progression-free survival as primary endpoint BERKELEY HEIGHTS, N.J. , June 18, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated...

BERKELEY HEIGHTS, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a...

BERKELEY HEIGHTS, N.J., May 31, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced today that the first patient has been accrued to a new randomized trial of tesetaxel as initial...

-- New Data for Response, Survival, and Safety to be Presented at ASCO -- Results Support Projections for New Randomized Trial BERKELEY HEIGHTS, N.J., May 24, 2012 (GLOBE NEWSWIRE) -- Genta...

--Promising results for response and progression-free survival --Company to proceed with randomized trial BERKELEY HEIGHTS, N.J., May 22, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) today...

BERKELEY HEIGHTS, N.J., May 14, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) today reported results for the quarter ended March 31, 2012. For the first quarter of 2012, the Company...

-- TESEGAST Trial Opens in U.S., EU, and Asia -- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2nd-Line Treatment BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Genta...

-- TESEGAST Trial Opens in U.S., EU, and Asia -- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2nd-Line Treatment BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Genta...

BERKELEY HEIGHTS, N.J., April 24, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today the appointments of Dr. Brian Leyland-Jones and Richard J. Moran, as members of the Company's...

BERKELEY HEIGHTS, N.J., April 4, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today that its lead compound, tesetaxel, will be featured in multiple presentations of new clinical...